rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
5
|
pubmed:dateCreated |
2009-2-23
|
pubmed:abstractText |
AKT inhibitors containing an imidazopyridine aminofurazan scaffold have been optimized. We have previously disclosed identification of the AKT inhibitor GSK690693, which has been evaluated in clinical trials in cancer patients. Herein we describe recent efforts focusing on investigating a distinct region of this scaffold that have afforded compounds (30 and 32) with comparable activity profiles to that of GSK690693.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1464-3405
|
pubmed:author |
pubmed-author:ChoudhryAnthony EAE,
pubmed-author:ConchaNestor ONO,
pubmed-author:HeerdingDirk ADA,
pubmed-author:LeberJack DJD,
pubmed-author:McNultyKenneth CKC,
pubmed-author:MillerWilliam HWH,
pubmed-author:MinthornElisabeth AEA,
pubmed-author:RouseMeagan BMB,
pubmed-author:SchaberMichael DMD,
pubmed-author:SeefeldMark AMA,
pubmed-author:SunLihuiL,
pubmed-author:ZhangShuyunS
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1508-11
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:19179070-Animals,
pubmed-meshheading:19179070-Cell Line,
pubmed-meshheading:19179070-Cell Line, Tumor,
pubmed-meshheading:19179070-Crystallography, X-Ray,
pubmed-meshheading:19179070-Humans,
pubmed-meshheading:19179070-Oxadiazoles,
pubmed-meshheading:19179070-Protein Kinase Inhibitors,
pubmed-meshheading:19179070-Protein Structure, Secondary,
pubmed-meshheading:19179070-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:19179070-Structure-Activity Relationship
|
pubmed:year |
2009
|
pubmed:articleTitle |
Aminofurazans as potent inhibitors of AKT kinase.
|
pubmed:affiliation |
Oncology Chemistry, GlaxoSmithKline, Collegeville, PA 19426, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|